The saccharide constituents of lipopolysaccharides (LPS) of Proteus spp. vary with the strain and contain unique components about which little is known. The biological activities of LPS and lipid A from S-and R-forms of 10 Proteus strains were examined. LPS from all S-form Proteus strains was lethal to D-(þ)-galactosamine (GalN)-loaded, LPS-responsive, C3H=HeN mice, but not to LPS-hypo-responsive C3H=HeJ mice. P. vulgaris O25 LPS evoked strong anaphylactoid reactions in N-acetylmuramyl-L-alanyl-Disoglutamine (MDP)-primed C3H=HeJ mice. LPS from S-and R-form Proteus strains induced production of nitric oxide (NO) and tumour necrosis factor (TNF) by macrophages isolated from C3H=HeN but not C3H=HeJ mice. Lipid A from Proteus strains also induced NO and TNF production, although lipid A was less potent than LPS. The effects of LPS were mainly dependent on CD14; LPS-induced NO and TNF production in CD14 þ J774.1 cells was significantly greater than in CD14 À J7.DEF.3 cells. All LPS from Proteus strains, and especially from P. vulgaris O25, exhibited higher anticomplementary activity than LPS from Escherichia coli or Pseudomonas aeruginosa. Polymyxin B inactivated proteus LPS in a dose-dependent manner, but these LPS preparations were more resistant to polymyxin B than E. coli LPS. CAP18 109-135 , a granulocyte-derived peptide, inhibited proteus LPS endotoxicity only when the LPS:CAP18 109-135 ratio was appropriate, which suggests that CAP18 109-135 acts through a different mechanism than polymyxin B. The results indicate that LPS from Proteus spp. are potently endotoxic, but that the toxicity is different from that of LPS from E. coli or Salmonella spp. and even varies among different Proteus strains. The variation in biological activities among proteus LPS may be due to unique components within the respective LPS.
Introduction
Bacteria belonging to the genus Proteus, especially P. mirabilis, are the second most common cause of urinary tract infections, and a major cause of nosocomial infections [1] ; these bacteria also cause wound infection, pneumonia and septicaemia. Several pathogenic factors associated with Proteus spp. have been described, including fimbriae, flagella, urease, IgA and IgG proteases, haemolysins and outer-membrane lipopolysaccharide (LPS) [2] . Chemical and serological studies of LPS from Proteus strains have demonstrated that it has uncommon constituents, such as 4-amino-4-deoxy-L-arabinosyl residues (AraN) in the 3-deoxyoctulosonic acid (KDO) and lipid A regions [3, 4] , D-galacturonic acid in the core region, and amino and uronic acids and unusual sugars in the O-polysaccharide domain. These constituents are not present in other members of the Enterobacteriaceae [5] . Although chemical analyses have yielded substantial information about proteus LPS, there is as yet little information available about its biological activities. Proteus-type lipid A has been synthesised, and it is similar to synthetic Escherichia coli (compound 506) and Salmonella minnesota R595 lipid A analogues with respect to B cell mitogenic activity, lethality and induction of a local Shwartzman reaction [6] . However, the actions of the uncommon constituents in proteus LPS have not yet been investigated. In this study, the extent to which unique constituents from the polysaccharide, KDO and lipid A regions of proteus LPS influence the biological activities of the bacteria was investigated.
Materials and methods

Bacterial strains
P. mirabilis strains of serotypes O10 (PrK 19=57), O13 (PrK26=57), O23 (PrK41=57), O26 (PrK49=57) and O43 (PrK69=57) and P. vulgaris strain PrK48=57 of serotype O25 were obtained from the Czech National Collection of Type Cultures, Prague, Czechoslovakia. P. vulgaris strain OX19 of serotype O1 was a kind gift from Dr S. Kaluzewski, National Institute of Hygiene, Warsaw, Poland. P. mirabilis strains S1959 (O3), R45=S1959 (Re-chemotype) and R110=S1959 (Rachemotype) were obtained from the Institute of Microbiology and Immunology, University of Lodz, Poland.
LPS and lipid A
R-chemotype LPS was prepared from P. mirabilis strains R45 and R110 by the phenol-chloroform, petroleum-ether, extraction procedure [7] . S-form proteus LPS was prepared by the phenol-water method with modification [8] and purified as reported previously [9] . Klebsiella pneumoniae O3 LPS was prepared from K. pneumoniae strain LEN-1 (O3:K1 À ) by the phenolwater method and purified as described previously [10] . P. mirabilis lipid A was obtained after hydrolysis of P. mirabilis S1959 (O3) LPS with acetic acid 1%. E. coli F515 LPS (Re-chemotype) was kindly provided by E. Th. Rietschel, Forschungszentrum, Borstel, Germany. S. minnesota R595 LPS (Re-chemotype) was generously provided by K. Hisatsune, Josai University, Sakado, Japan. Pseudomonas aeruginosa LPS was a gift from Y. A. Knirel, N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia. E. coli O55 LPS and S. minnesota R60 (Rachemotype) LPS were obtained from List Biological Laboratories, Campbell, CA, USA. Synthetic E. colitype lipid A (compound 506) [11] was provided by Daiichi Pharmaceutical, Tokyo, Japan.
Stock solutions of LPS and lipid A were prepared by dissolving the compounds in endotoxin-free water or triethylamine 0.025% (1 mg=ml), respectively; stocks were stored at 48C. Immediately before use, stock solutions were diluted appropriately in endotoxin-free distilled water, endotoxin-free saline or RPMI-1640 medium.
The chemical structures of several proteus LPS, especially those of the O-polysaccharide repeating unit, have been well characterised [3, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The Opolysaccharide structures of S-form LPS used in the experiments are shown in Table 1 
Reagents
Synthetic muramyl dipeptide (MDP) [26] was provided by Daiichi Pharmaceutical, Tokyo, Japan. Murine recombinant interferon-gamma (INF-ª) and human recombinant tumour necrosis factor-AE (TNF-AE) were provided by Dainippon Pharmaceutical and Shionogi Pharmaceutical, Osaka, Japan, respectively. Polymyxin B (PmxB; mol. wt 1190) and D(þ)-galactosamine (DGalN) were purchased from Sigma. Human CAP18 is a 140 amino acid protein [27] ; CAP18 109-135 is a 27 amino acid segment (FRKSKEKIGKEFKRIVQ RIKDFLRNLV) in the C-terminal region of CAP18 which has been identified as the LPS-neutralising and antimicrobial domain [28] . CAP18 109-135 peptide (mol. wt 3480) was synthesised by Chiron Mimotopes Peptide Systems San Diego, CA, USA. The peptide was subjected to fast atom bombardment mass spectrometry and yielded the expected parent M þ H ions within limits (1 unit of mass). CAP18 109-135 was dissolved in saline, divided into aliquots and stored at À808C; samples were thawed only immediately before use.
Animals
LPS-responsive C3H=HeN mice and LPS-hypo-responsive C3H=HeJ mice were obtained from Nippon Clea, Tokyo, Japan and maintained in the animal facility at the Jichi Medical School under standard conditions. Female C3H=HeN mice were used at 10-15 weeks of age, and female or male C3H=HeJ mice were used at 8-12 weeks of age.
Lethal toxicity in galactosamine-loaded mice
The lethal toxicity of LPS for mice was determined as described previously [29] . C3H=HeN and C3H=HeJ mice were inoculated intraperitoneally (i.p.) with 0.2 ml of LPS solution (10-10 000 ng of LPS=mouse) together with 0.5 ml of D-GalN solution (18 mg=mouse). Mortality was scored 48 h after the challenge and the LD50 was calculated.
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Induction of anaphylactoid and lethal reactions in muramyl dipeptide (MDP)-primed mice
Assays for anaphylactoid and lethal reactions were performed as described previously [30] . Female or male C3H=HeJ mice were inoculated intravenously (i.v.) with 100 ìg of MDP dissolved in 0.2 ml of pyrogen-free saline. Then, 4 h later, mice were challenged by i.v. injection with LPS (6-100 ìg of LPS in pyrogen-free saline=mouse), observed for 1 h, and the incidence of anaphylactoid reactions and death was recorded. Anaphylaxis was characterised by rolling, jumping, severe convulsions and unconsciousness 5-20 min after injection of LPS and by occasional deaths 10-30 min after the injection. Mice were monitored further every 24 h for 3 days, although all deaths occurred within 1 h of injection.
Murine macrophages
Mouse peritoneal exudate cells (PECs) were harvested by peritoneal lavage 4 days after i.p. injection of 1.5 ml of Brewer thioglycolate 3% broth (Difco Laboratories, Detroit, MI, USA) as described previously [31] . The PECs were washed with serum-free RPMI 1640 medium (ICN Biomedicals, Costa Mesa, CA, USA) containing 4 mM L-glutamine, penicillin 100 U=ml and streptomycin 100 ìg=ml and seeded to a concentration of 2 3 10 5 cells=well in 96-well plates (Nunc, Roskilde, Denmark). The cells were incubated for 3 h at 378C in air 95%=CO 2 5%, and then washed with serum-free RPMI 1640 medium to remove nonadherent cells. The remaining adherent cells consisted of . 95% macrophages as determined by morphology and non-specific esterase staining. These cells were cultured in the presence of various concentrations of test preparation in 200 ìl of RPMI 1640 medium containing heat-inactivated fetal bovine serum (FBS; JRH Biosciences, Lenexa, KS, USA) 5% with and without IFN-ª 0:5 U=ml for C3H=HeJ-derived and C3H=HeN-derived cells, respectively. The culture supernates were collected after 3.5 h for the TNF assay and after 48 h for the NO assay.
Murine macrophage-like cells
Mouse macrophage-like J774.1 cells were kindly provided by Dr T. Suzuki, University of Kansas Medical Center. An LPS-resistant, membrane CD14 À mutant cell line, J7.DEF.3, was derived from J774.1 cells as described previously [32] . These cells were grown in flasks (Nunc) with RPMI 1640 containing FBS 5%, 4 mM L-glutamine, penicillin 100 U=ml and streptomycin 100 ìg=ml at 378C, in air 95%=CO 2 5%. Once the cells reached confluence, fresh culture medium was applied and the cells were maintained for a further 24 h. Cells were then collected by vigorous pipetting and were centrifuged. The cells were washed once with the culture medium and seeded into 96-well culture plates at 2 3 10 5 cells=well in 180 ìl of RPMI 1640 medium containing FBS 5% and INF-ª (1 or 2 U=ml) for 1 h. Various test preparations (20 ìl) were then added to each well and the cells were cultured for a further 48 h, after which culture supernates were collected for NO assay.
TNF assay
TNF activity was determined as described previously [33] with a functional cytotoxic assay in TNF-sensitive 
AlaLys, 1,9-dicarboxy-2,8-diaminononane; AltA, alturonic acid.
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L929 cells (donated by Dr M. J. Parmely, University of Kansas Medical Center).
Nitric oxide (NO) assay
NO formation was measured as the stable end product, nitrite (NO À 2 ), in the supernates of macrophage or macrophage-like cell cultures by the Griess reagent method as described previously [33] .
Assay for LPS anti-complementary activity
Various amounts of LPS were dissolved in distilled water (12.5 ìl) and fresh human serum (50 ìl) was added to the LPS solution as a source of complement. The mixture was incubated for 30 min at 378C, and LPS anti-complementary activity in the mixture was determined with a liposome-based assay for measuring total complement activity (C3H=HA test; Wako Chemical Industries, Osaka, Japan) [34] . The kit contained dinitrophenyl (DNP)-labelled liposomes containing entrapped glucose-6-phosphate dehydrogenase, anti-DNP antibody and substrate (NAD þ ). Liposome lysis caused by complement activity was detected spectrophotometrically by determination of the activity of released glucose-6-phosphate dehydrogenase. Complement activity in the samples was quantified as a function of the rate of absorbance increase (˜A=min).
Assay for LPS sensitivity to polymyxin B or CAP18 109-135
Polymyxin B and CAP 109-135 are capable of neutralising the endotoxicity of LPS and lipid A. LPS and lipid A preparations were mixed with polymyxin B or CAP 109-135 , or neither as control, and incubated at 378C for 30 min. The solutions were added to J774.1 cell cultures which were maintained for a further 48 h. The culture supernates were then collected and NO in the supernates was assessed. Attenuation of LPS endotoxicity by polymyxin B or CAP 109-135 was indicated by a decline in the NO yield. CAP18 109-135 alone (0:1-10 ìg=ml) did not induce any detectable NO production in J774.1 cells.
Results
Lethal toxicity of proteus LPS in GalN-loaded mice
GalN-loaded mice are markedly susceptible to LPS endotoxicity [29] . The lethal effects of LPS from P. mirabilis, P. vulgaris, E. coli O55 and K. pneumoniae O3 were compared in GalN-loaded C3H=HeN and C3H=HeJ mice ( Table 2 ). All proteus LPS preparations were toxic to C3H=HeN mice to a degree similar to that of LPS from other members of the Enterobacteriaceae. The LD50 values of LPS from P. mirabilis O23 and O26 were each c. 52 ng, which was similar to the values for E. coli O55 LPS and K. pneumoniae O3 LPS. LPS from P. vulgaris O25 was significantly less lethal than LPS from the other strains (LD50 versus E. coli O55 LPS; p , 0:05). In contrast, LPS preparations were not lethal in C3H=HeJ mice.
Anaphylactoid and lethal reactions evoked by proteus LPS in MDP-primed C3H=HeJ mice S-form LPS preparations from some strains of bacteria, including Salmonella spp., Porphyromonas gingivalis, Prevotella intermedia and K. pneumoniae O3 [30, 35; personal communication by H. Takada, Tohoku Uni- versity, Sendai, Japan] induce lethal anaphylactoid reactions in MDP-primed mice. The polysaccharide portion of LPS apparently plays a key role in the induction of anaphylaxis, because lipid A and Rchemotype LPS from E. coli and Salmonella spp. do not elicit the reaction. LPS and lipid A preparations from Proteus spp. were examined for their ability to induce lethal anaphylaxis in MDP-primed C3H=HeJ mice (Table 3) . K. pneumoniae O3 LPS elicited anaphylactic reactions that killed all mice within 20 min after injection. E. coli O55 LPS did not induce such reactions. Of eight S-form LPS, Re-chemotype LPS and lipid A preparations from Proteus spp., only P. vulgaris O25 LPS evoked severe anaphylaxis similar to that seen with K. pneumoniae O3 LPS. P. mirabilis O43 and O10 LPS showed less activity, whereas P. mirabilis O23, O13, O26 and O3 LPS and P. vulgaris O1 LPS had no effect in the mice.
TNF and NO production in C3H=HeN and C3H=HeJ macrophages
Enterobacterial LPS and Ps. aeruginosa LPS activate peritoneal C3H=HeN mouse macrophages inducing TNF and NO production, whereas their effects on C3H=HeJ macrophages are minimal [33, 36] . S-form LPS from P. mirabilis O23 and O26 and from P. vulgaris O25 dose-dependently induced both TNF and NO production in C3H=HeN macrophages (Fig. 1a) . The threshold concentration was 0:1-1 ng=ml and maximal induction occurred at 10 ng=ml; these doseresponse relationships were similar to that of E. coli O55 LPS. The dose-response relationships of other Sform LPS from P. mirabilis O3, O10, O13, O43 and from P. vulgaris O1 were similar (data not shown). Thus, differences in the sugar components in Opolysaccharides among proteus LPS had little effect on TNF or NO production. Ra-and Re-chemotype LPS of Proteus strains induced production of TNF and NO in C3H=HeN macrophages, and the effect was similar to that of salmonella Ra-and Re-chemotype LPS (Fig.  1b) . Proteus lipid A induced TNF and NO production in a manner that was qualitatively similar to synthetic E. coli lipid A, although its potency was c. 100 times less than Re-chemotype LPS (Fig. 1c) . The endotoxicity of lipid A was thus augmented when Opolysaccharide or R-core oligosaccharide was present.
In contrast, C3H=HeJ macrophages produced little or no TNF and NO in response to any of the endotoxic preparations tested (Fig. 1 and other data not shown).
CD14-dependent macrophage activation by proteus LPS
Macrophage activation in response to enterobacterial LPS and Ps. aeruginosa LPS is mediated mainly by the cell-surface form of CD14 (mCD14) [33, 36, 37] . However, an alternative CD14-independent pathway has been suggested [32] . The CD14 dependence of proteus LPS-induced macrophage activation was examined with CD14 þ , murine macrophage-like J774.1 cells [32, 38] and their CD14 À mutant, J7.DEF3 cells [32, 33] . All LPS preparations from Proteus strains tested induced dose-dependent increases in TNF and NO production in both J774.1 and J7.DEF.3 cells (Fig.  2) . However, dose-response curves obtained from the 
CD14
À mutant cells were shifted to concentrations 10-1000 times higher than those of CD14 þ parental cells. This confirmed that proteus LPS-induced macrophage activation was largely dependent on CD14.
Anti-complementary activity of proteus LPS
Because only K. pneumoniae O3 and P. vulgaris O25 LPS potently induced lethal anaphylaxis in MDPprimed C3H=HeJ mice, and LPS from K. pneumoniae O3 was known to have extremely high anti-complementary activity [39] , it was considered worthwhile to examine proteus LPS, especially P. vulgaris O25 LPS, for anti-complementary activity. All LPS preparations tested exhibited concentration-dependent anti-complementary activity (Fig. 3) . LPS from K. pneumoniae O3 and P. vulgaris O25 were the most effective; they elicited c. 60% inhibition of complement at an LPS concentration of 1 ìg=ml. The inhibitory effects of P. mirabilis O23, O43, O13, O26, O3 and O10 LPS and P. vulgaris OX19(O1) LPS were also relatively strong, whereas the effects of E. coli O55 LPS and Ps. aeruginosa LPS were weak.
Sensitivity of proteus LPS to polymyxin B
Proteus spp. are naturally resistant to polymyxin B. Polymyxin B neutralises many of the biological activities of LPS by binding to its lipid A domain. Therefore this study examined whether the endotoxicity of proteus LPS and lipid A was affected by treatment with polymyxin B. The magnitude of the effect was estimated from the change in LPS-evoked NO production by J774.1 cells in the presence of polymyxin B. As The culture supernates were collected for TNF assay after 3.5 h (left panels) and after 48 h for NO assay (right panels). Each point represents the mean (bar SE) for three samples and the data represent one of two experiments with similar results. a, P. mirabilis O23 (d, s); P. mirabilis O26 (j, h); P. vulgaris O25 (m, n); E. coli O55 (r, e). b, P. mirabilis Re-chemotype (d, s); P. mirabilis Ra-chemotype (m, n); S. minnesota Re-chemotype (j, h); S. minnesota Ra-chemotype (r, e). c, P. mirabilis lipid A (d, s) and E. coli synthetic lipid A (j, h). shown in Fig. 4a , polymyxin B inactivated LPS from P. mirabilis O23, O26 and P. vulgaris O25 dosedependently, but proteus LPS were obviously more resistant to polymyxin B than LPS from E coli O55. Similarly, LPS from S-form P. mirabilis O43, O13, O3, O10 and P. vulgaris O1 were also resistant to polymyxin B (data not shown).
A low concentration (1 ìg=ml) of polymyxin B potently neutralised S. minnesota Ra-chemotype LPS, whereas a substantially higher concentration (100 ìg=ml) was necessary to neutralise P. mirabilis Ra-chemotype LPS (Fig. 4b) . Both S. minnesota and P. mirabilis Re-chemotype LPS were more resistant to polymyxin B than E. coli Re-chemotype LPS (Fig. 4c) . Moreover, a relatively low concentration of polymyxin B neutralised P. mirabilis lipid A as well as E. coli lipid A (Fig. 4d) . To evaluate these results more precisely, the relative potency of polymyxin B in neutralising test preparations was calculated as the ID50=stimulant concentration value (Table 4 ). In the cases of R-chemotype LPS and lipid A, the values were also calculated on a molecular basis. The neutralising values for S-form LPS from Proteus spp. were 6-500-fold higher than that for E. coli O55 LPS, indicating that proteus LPS were much more resistant to polymyxin B than E. coli O55 LPS.
Sensitivity of proteus LPS to CAP18 109-135
The C-terminal 27 amino-acid fragment of CAP18, designated CAP18 109-135 , has the ability to neutralise LPS endotoxicity [28, 40] . Therefore, the sensitivity of proteus LPS to CAP18 109-135 was examined with the same protocol that was used to characterise the effects of polymyxin B. The activities of P. mirabilis O23 LPS were dose-dependently affected by CAP18 109-135 between 0.1 and 1.3 ìg=ml (Fig. 5a ). Although the effects of P. mirabilis Ra-and Re-chemotype LPS and lipid A on NO synthesis were also reduced by treatment with CAP18 109-135 , the optimal LPS: CAP18 109-135 ratios were observed within that range (Fig. 5b, c and d ). Higher concentrations of CAP18 109-135 neutralised LPS less effectively. The endotoxicity of LPS from P. mirabilis O43, O13, O26, O3 and O10, P. vulgaris O25 and O1, E. coli O55, S. minnesota R60 and R595, as well as synthetic E. coli lipid A, was also reduced by CAP18 109-135 treatment (data not shown). The relative potency of CAP18 109-135 in neutralising LPS and lipid A was calculated as ID50 stimulant concentration values (Table 4) . These neutralising values for S-form LPS from Proteus spp. were similar to that for E. coli O55 LPS.
Discussion
Although Proteus is a genus of the family Enterobacteriaceae, the chemical constituents of LPS from Proteus spp. are different from LPS of other enterobacteria. For instance, the fatty acid composition of lipid A from Proteus spp. differs from that of E. coli and S. minnesota lipid A, and the AraN residue is linked to the phosphate residue of the glucosamine backbone at the 49 position [3] . Uncommon constituents that are not detected in other enterobacterial LPS are found in the polysaccharide chains of proteus LPS; these include D-galacturonic acid in the core region as well as uronic acids and unusual sugars and amino acids in the O-polysaccharide portion of LPS. Furthermore, N-acetylglucosamine and mannose -which are recognised by mannose-binding protein (MBP) -are found in the polysaccharide chains of proteus LPS. Opolysaccharide structures vary among LPS from Proteus spp. and this might be expected to cause variation in the endotoxic actions of the respective Proteus strains. LPS from Proteus strains were potently endotoxic, exhibiting properties similar to other enterobacterial LPS. Proteus LPS killed GalN-sensitised C3H=HeN mice but not C3H=HeJ mice, activated C3H=HeN but not C3H=HeJ macrophages, and were highly dependent on CD14 for activation of C3H=HeN macrophages. Proteus LPS were comparatively resistant to the action of polymyxin B which neutralises the toxicity of LPS from E. coli and Salmonella spp. However, there was obvious variability in endotoxic potency among proteus LPS with respect to anaphylactoid reactions, anticomplementary activity and sensitivity to polymyxin B.
Lipid A is the principal endotoxic moiety of LPS. Shimizu et al. [6] reported that the endotoxicities of synthetic Proteus-and E. coli-type lipid A were similar, based on their mitogenicity in murine splenic cells and lethal toxicity in GalN-sensitised mice; however, the capacity of proteus lipid A to induce a local Shwartzman reaction was weak.
In the present study, the abilities of P. mirabilis lipid A and synthetic E. coli lipid A to induce TNF and NO production in murine macrophages were approximately equal. The endotoxic potency of lipid A was substantially lower than that of S-form or Re-chemotype LPS.
To obtain maximal production of TNF and NO by macrophages, it was necessary to use concentrations of lipid A 10-100 times higher than were used with Rchemotype LPS. Thus, the presence of the polysaccharide domain of LPS apparently enhances the endotoxicity of lipid A. LPS polysaccharide-induced modulation of endotoxicity -including modulation of local skin responses [41] , complement activation [39, 42] , haemagglutination [43] , macrophage arachidonic acid metabolism [44] , activation of B cells and macrophages [45, 46] and induction of TNF=NO production [32, 47] -has also been reported with LPS from E. coli, Salmonella spp. and K. pneumoniae.
Despite the unique components in their polysaccharide chains, proteus LPS did not exhibit any special endotoxicity.
TNF and NO are thought to be powerful mediators of endotoxic shock. It is known that the soluble and surface forms of CD14 and serum factors such as lipopolysaccharide-binding protein (LBP) [48] and septin [49] participate in macrophage activation by LPS [37] . The binding of LPS-LBP complexes to mCD14 stimulates macrophages to produce large quantities of active molecules such as IL-1, TNF, IL-6 and NO [50] . However, it has been suggested that CD14-independent pathways may also be present [32, 33, [51] [52] [53] . The finding that CD14 þ J774.1 cells produced significantly more TNF and NO in response to proteus LPS than CD14 À J7.DEF cells suggests that proteus LPS recognition by macrophages is primarily mediated by CD14.
The induction of anaphylaxis by LPS depends upon the [30, 54, 55] . TNF production was apparently not essential for induction of anaphylaxis, as the reaction was elicited in C3H=HeJ mice in the absence of detectable TNF production [35] . In the present study, only P. vulgaris O25 LPS induced strong anaphylactoid reactions like those evoked by K. pneumoniae O3 LPS, and little or no TNF or NO production was detected, confirming that TNF and NO do not participate in LPSinduced anaphylaxis.
The ability to induce anaphylaxis is believed to be associated with potent activation of complement. It was observed that LPS from P. vulgaris O25 and K. pneumoniae O3 possessed strong anti-complementary activity. K. pneumoniae O3 LPS has a mannose homopolymer in its O-polysaccharide chain that binds to MBP and strongly activates complement via the lectin pathway [39, 55, 56] . Unlike mannose, other sugars -including N-acetylglucosamine (GlcNAc), Nacetylmannosamine, rhamnose and fucose -have an equatorial conformation at the 3-and 4-OH groups or at the 2-and 3-OH groups, which can form hydrogen bonds with lectins [57] . Because the O-polysaccharide chains of P. vulgaris O25 LPS contain N-acetylglucosamine, rhamnose, ribose and an unusual acidic component -an ether of glucose with (R)-lactic acid (3-O-[(R)-1-carboxyethyl]-D-glucose) -they may be able to form a centre for hydrogen bonding leading to complement activation via the lectin pathway. All proteus LPS with the exception of P. mirabilis O3 LPS, which has GlcNAc in its core oligosaccharide [58] , contain GlcNAc in their polysaccharide moieties. Consequently, proteus LPS-induced complement activation may be generally mediated by the lectin pathway.
E. coli O55 LPS also contains a GlcNAc residue, but its GlcNAc residue binds to repeating units of O-polysaccharide at position 3, and GlcNAc at position 3 lacks the ability to bind MBP. Ps. aeruginosa Fisher 2 Opolysaccharide does not contain GlcNAc. Consistent with the discussion above, LPS from E. coli O55 and Ps. aeruginosa Fisher 2 possessed little if any anti-complementary activity. It is known that enterobacterial LPS is sensitive to polymyxin B. Nevertheless, like the living organisms, proteus LPS were relatively resistant to polymyxin B-induced inactivation. Most proteus LPS possess two AraN residues in the KDO=lipid A region [3, 4, 59] , which may provide them with their resistance to polymyxin B. P. mirabilis R110 LPS contains AraN, and Re-chemotype LPS from P. mirabilis R45 has two AraN residues, one bound to KDO and the other bound to the ester-linked phosphate group of lipid A [4] . S. minnesota R595 LPS has one lipid A-bound AraN residue [60] . The study found that proteus LPS with AraN residues were resistant to polymyxin B. E. coli Sform LPS and lipid A (compound 506) do not contain AraN [61] , nor do E. coli F515 (Re-chemotype) and S. minnesota R60 (Ra-chemotype) LPS [62, 63] . P. mirabilis lipid A probably loses its AraN residues during the process of extraction with mild acid hydrolysis. These LPS and lipid A were sensitive to polymyxin B which supports the idea that the presence of AraN residues in proteus LPS is associated with resistance to polymyxin B-evoked inactivation. The O-polysaccharide chain in LPS may also protect LPS from the destructive action of polymyxin B, because S-form LPS were more resistant than lipid A or R-chemotype LPS.
Treatment of proteus LPS and lipid A with CAP18 109-135 together with polymyxin B weakened their endotoxicity. However, the profiles of CAP18 109-135 -induced inhibition were quite different from those of polymyxin B, suggesting that the mode of action of the two substances was different. Polymyxin B dose-dependently attenuated the activity of LPS, whereas the suppressive action of CAP18 109-135 was not dose-dependent. Instead, as with the zones of precipitation in antigen-antibody reactions, optimal CAP18 109-135 : LPS ratios were required to obtain suppression. CAP18 109-135 peptide may bind LPS polyvalently, thereby hindering access of LPS to target cells. Another indicator of the differences between CAP18 109-135 and polymyxin B was their spectra of sensitivity among Proteus LPS. Proteus S-form and Rchemotype LPS were resistant to polymyxin B, whereas they were comparatively sensitive to the CAP18 109-135 , which suggests that AraN residues do not affect CAP18 109-135 binding to LPS.
